Global Antiviral Drugs Market is Expected to Reach USD 37.40 billion, Global Antiviral Drugs Market is Expected to Reach | Page 3






Influenza
Others
Y-o-Y Growth Analysis, By Application
Market Attractiveness Analysis, By Application
Market Share Analysis, By Application
2) By Target:








Introduction
DNA polymerase
NS3 Protease
Reverse transcriptase
Others
Y-o-Y Growth Analysis, By Target
Market Attractiveness Analysis, By Target
Market Share Analysis, By Target
3) By End Users:







Introduction
Hospitals/Clinics
Research Institutes
Laboratory Centers
Y-o-Y Growth Analysis, By End Users
Market Attractiveness Analysis, By End Users
Market Share Analysis, By End User
The market has also been geographically segmented into North America, Europe, Asia-
Pacific and the Middle-East and Africa. North America is expected to command the major
market share of 34.0% in the global antiviral drugs market. Whereas, Asia-Pacific is
projected to grow at the highest CAGR of 6.12% during forecast period 2016-2021.For more
of regional analysis check out the following reports.





North America Antiviral Drugs Market
Europe Antiviral Drugs Market
Asia-Pacific Antiviral Drugs Market
Latin America Antiviral Drugs Market
Middle East and Africa Antiviral Drugs Market
The major companies dominating the global Antiviral Drugs market are Johnson & Johnson
(USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA),
Merck and Co. Inc (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United
Kingdom), Gilead Sciences (USA), and Abbott Laboratories (USA).